Evidence map›Paper›PMID 42539466›Full record

ArticleFrontiers in immunology2026

Guanxinjing ameliorates coronary microvascular dysfunction in myocardial ischemia-reperfusion injury by alleviating inflammation and restoring endothelial function.

Yaoting Wang, Lan Li, Liang Jin, Shikai Zhan, Hai Ren, Jiao Zhao, Qiuru Wang, Yiqiong Wang, Shudong Lin, Jiaxing Xin and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yaoting Wang *College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Lan Li *School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Liang Jin *School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Shikai ZhanCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Hai RenResearch and Development Department, Baoding Traditional Chinese Medicine Pharmaceutical Co., Ltd., Baoding, China.
Jiao ZhaoResearch and Development Department, Baoding Traditional Chinese Medicine Pharmaceutical Co., Ltd., Baoding, China.
Qiuru WangCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yiqiong WangCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Shudong LinCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Jiaxing XinCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yao DaiCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yifan ZhouCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Ting ZhangCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Qian LiuSchool of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yunyun LuSchool of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yiqi ZhuSchool of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Jiangyue WuSchool of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Jiayan LinSchool of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Shujing ZhangInnovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.
Ling ZhangCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronary microvascular dysfunction (CMD) secondary to myocardial ischemia-reperfusion injury (MIRI) is characterized by profound inflammatory activation and endothelial impairment. Guanxinjing compound (GXJC) is a clinical drug widely used for coronary heart disease and angina pectoris closely associated with coronary microvascular function. Its efficacy and mechanisms against MIRI-induced CMD remain elusive. Methods: The chemical profiling of GXJC was performed via UHPLC-Q-Exactive HRMS. Network pharmacology analysis (NPA) screened the core targets and key pathways of GXJC. Results: UHPLC-Q-Exactive HRMS analysis identified 256 bioactive compounds in GXJC. NPA predicted the TNF signaling pathway as a potential key mechanism through which GXJC may ameliorate MIRI. Conclusion: Our study demonstrates that GXJC acts as a potential therapeutic agent for MIRI-induced myocardial injury and associated microvascular endothelial dysfunction through the dual modulation of inflammatory cascades and microvascular endothelial protection. These mechanistic insights support its future clinical development for microvascular complications following revascularization.

Indexed as

Coronary VesselsDrugs, Chinese HerbalEndothelium, VascularMicrovesselsMyocardial Reperfusion InjuryAnimalsApoptosisDisease Models, AnimalHumansHuman Umbilical Vein Endothelial CellsInflammationMaleMiceMice, Inbred C57BLSignal TransductionDrugs, Chinese Herbalendothelial functionGuanXinJinginflammationmicrocirculationmyocardial ischemia-reperfusion injury

Identifiers

PMID42539466
PMCPMC13423699

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.